Amerikanische Gesellschaft für Hirudotherapie

Sodium citrate 4% versus heparin as a lock solution in hemodialysis patients with central venous catheters.

Research article published in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2013)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyKlinische StudienArzneimittelentwicklungYon et al. · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013

Abstract

PURPOSE: The effects of heparin versus sodium citrate 4% as a lock solution on catheter-related infections (CRIs), catheter patency, and hospitalizations in long-term hemodialysis patients with central venous catheters (CVCs) were compared. METHODS: Data for patients receiving heparin lock solutions were collected from July 2008 to July 2009. Data on patients receiving sodium citrate 4% lock solution were collected from September 2009 through December 2010. Patients who were receiving the heparin lock solution who continued to have a CVC in September 2009 were transitioned from heparin to sodium citrate catheter 4% lock solution. New patients with CVCs placed after September 2009 received sodium citrate 4% without a period of using heparin lock solution. Pertinent information on patient medical history, bleeding or clotting events, infections, and hospitalization was collected. Data were collected retrospectively for the heparin group and prospectively for the sodium citrate group. RESULTS: Data were collected from 360 patient-months among 60 patients during the heparin treatment period and from 451 patient-months among 58 patients during the sodium citrate period. Thirty-three patients were common to both study groups. There were significantly more CRIs and CRIs per 1000 catheter-days in the heparin than the sodium citrate treatment group. Secondary outcomes of hospitalizations and catheter thrombosis were comparable. CRIs and thrombosis led to significantly more catheter exchanges or removals in the heparin group than the sodium citrate group. CONCLUSION: In patients with long-term hemodialysis catheters, a lock solution of sodium citrate 4% was associated with fewer CRIs and similar effectiveness when compared with heparin 5000 units/mL.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal Article
Indexed MeSH termsAgedAnticoagulantsBuffersCaliforniaCatheter-Related InfectionsCatheterization, Central VenousCentral Venous CathetersCitratesFemaleHeparinHumansMale

Zusammenfassung

The effects of heparin versus sodium citrate 4% as a lock solution on catheter-related infections (CRIs), catheter patency, and hospitalizations in long-term hemodialysis patients with central venous catheters (CVCs) were compared. Data for patients receiving heparin lock solutions were collected...

Warum dies für die Hirudotherapie relevant ist

This comparative study compared sodium citrate 4% versus heparin 5000 U/mL as catheter lock solutions in long-term hemodialysis patients with central venous catheters, encompassing 360 and 451 patient-months respectively. Sodium citrate 4% was associated with significantly fewer catheter-related infections and comparable rates of catheter thrombosis and hospitalizations relative to heparin. For ASH's domain, this study touches on anticoagulant lock strategies relevant to maintaining catheter patency, a peripheral topic. However, the study has no connection to leeches, hirudotherapy, or the leech secretome; any relevance is limited to the broad context of anticoagulant use in clinical practice, and no leech-derived agents or concepts are discussed.

Zitation

Sodium citrate 4% versus heparin as a lock solution in hemodialysis patients with central venous catheters.

Yon et al. · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.